Abstract 127P
Background
There is no widely used prognostic tool to demonstrate the benefit of oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX4) in patients with advanced hepatocellular carcinoma (HCC). We aimed to establish the prognostic score and demonstrate the real-world efficacy of FOLFOX4 in Thai patients.
Methods
Between August 2017 and December 2021, 58 patients with HCC treated with FOLFOX4 were identified. Efficacies of FOLFOX4, including overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), were assessed. The prognostic score was constructed by stepwise cox proportional hazards regression combined with clinical experience to select variables for the best model.
Results
44 patients (76%) received FOLFOX4 as first-line systemic therapy. The efficacies of FOLFOX4 in the entire cohort were ORR of 8.6% and clinical benefit rate (CBR) of 29.3%. The median OS and PFS were 4.8 and 3.7 months, respectively. Four variables were included in the new prognostic score to predict 6-month overall survival based on their clinical relevance: L, the presence of lung metastasis; A, alcoholic cirrhosis; B, elevated total bilirubin; and S, sorafenib naive. The new prognostic "LABS" score classified all patients into low-, intermediate-, and high-risk groups, demonstrating the median OS of 9.3, 4.2, and 2.1 months, respectively (P<0.0001). The C-index and area under receiver operating characteristic curve of this score were 0.71 and 0.73, respectively.
Conclusions
The FOLFOX4 regimen showed comparable ORR, PFS, and OS efficacy to previous reports. The proposed prognostic “LABS” score clearly discriminated patients who would have the benefit from FOLFOX4. Therefore, we suggest that FOLFOX4 should be considered as one of the options for those who cannot approach immunotherapy and targeted therapy, particularly with a low-risk score. However, this model should be further evaluated in the larger cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
99P - Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma
Presenter: Kazuaki Harada
Session: Poster viewing 02
100P - A prospective single arm study evaluating the outcome of neoadjuvant chemotherapy in locally advanced/border line resectable gall bladder cancer
Presenter: Pulkit Nag
Session: Poster viewing 02
101P - Cachexia index and sarcopenia in patients with advanced gastrointestinal cancer treated with chemotherapy during exercise intervention
Presenter: Song Ee Park
Session: Poster viewing 02
102P - A real-world study comparing apatinib combined with irinotecan versus irinotecan as second-line or above therapy in patients with advanced or metastatic gastric cancer
Presenter: Caiyun Nie
Session: Poster viewing 02
103P - Concurrent chemoradiotherapy with S-1 vs radiotherapy alone for older patients with esophageal cancer: A meta-analysis
Presenter: Jianquan Yang
Session: Poster viewing 02
104P - A multi-institutional epidemiological and oncological profile of gastrointestinal stromal tumors in the Lebanese population
Presenter: Mohamad Hadi El Charif
Session: Poster viewing 02
105P - The efficacy of nivolumab monotherapy for advanced gastric cancer depends on the HER2 status
Presenter: Yuichiro Nishibori
Session: Poster viewing 02
106P - Clinicopathologic and prognostic significance of FBXL5 expression in hepatocellular carcinoma
Presenter: Yoon Ah Cho
Session: Poster viewing 02
107P - Preliminary result of anatomical hepatectomy on recurrence based on preoperative circulating tumor cell status in hepatocellular carcinoma
Presenter: Xiaozhun Huang
Session: Poster viewing 02